More information: Matthew R. Brier et al, Unexpected Low Rate of Amyloid‐β Pathology in Multiple Sclerosis Patients, Annals of Neurology (2024). DOI: 10.1002/ana.27027.

If you have trouble speaking or swallowing, speech-language pathology can help. Takeaways. Late-onset multiple sclerosis is a form of the disease in which symptoms develop after age 50.

Multiple sclerosis (MS) ... The pathophysiology of MS likely involves a complex interplay between genetic and environmental factors, which are still incompletely identified.

A study of twins reveals two gut bacteria linked to multiple sclerosis, offering new targets for future treatments.

TOPLINE: Amyloid pathology typical of Alzheimer's disease (AD) is 50% lower in patients with multiple sclerosis (MS) than in those without the condition, an analysis of plasma biomarker data shows ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that is thought to be an autoimmune disorder where the body attacks itself by mistake. MS affects everyone differently ...

Associations of White Matter and Basal Ganglia Microstructure to Cognitive Fatigue Rate in Multiple Sclerosis. Frontiers in Neurology , 2022; 13 DOI: 10.3389/fneur.2022.911012 Cite This Page : ...

Considering the longevity of astrocytes, and their multiple contributions to CNS pathology, the authors suggest that astrocyte immune memory might be a possible mechanism behind chronic neurologic ...

And unlike secondary multiple sclerosis, which arises after many years of RRMS, PPMS is an initial diagnosis. The symptoms and pathophysiology of PPMS differ from other forms, too.

Recent highlights in MS coverage focus on biomarkers, pregnancy, and neurodegeneration. Physician’s Weekly has compiled a ...

Kessler Foundation study advances knowledge of role of brain pathology and cognitive fatigue in multiple sclerosis Kessler researchers demonstrate relationship between rate of cognitive fatigue in ...

I've been involved in MS care since before any treatments were available. I’m chief operating officer at Can Do Multiple Sclerosis, a nonprofit in the patient advocacy sphere of MS. I’m also a ...